Introduction Although standard schedule of gefitinib was the administration of 250 mg tablet
every day, many patients need dose reduction because of toxicities. However, the efficacy of …

Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …

Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) …

Purpose Gefitinib is safe for the treatment of non-small cell lung cancer (NSCLC), but some
patients experience toxicities and require dose reduction. The purpose of this study was to …

Background: Gefitinib treatment has come to be recognized as the standard therapy for
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …

Purpose To evaluate the relationship between the epidermal growth factor receptor (EGFR)
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …

Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …

The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of
screening for epidermal growth factor receptor (EGFR) mutations among select patients with …

BACKGROUND: Gefitinib is an effective treatment for patients with non-small cell lung
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …

Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as …